Children's Health Defense
Medical experts criticized the Centers for Disease Control and Preventionâs Thursday decision to recommend a ânew immunizationâ for newborns to protect against respiratory syncytial virus, or RSV, calling the move unnecessary and not worth the known risks.
ByÂ
The Centers for Disease Control and Prevention (CDC) on Thursday recommended the first-ever monoclonal antibody marketed as a defense for all newborns against respiratory syncytial virus, or RSV.
Beyfortus, also known as nirsevimab, is produced by pharma giants Sanofi and AstraZeneca.
Read Full Article Here…(childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)